|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Seraphin TP, Joko-Fru WY, Kamaté B,
Chokunonga E, Wabinga H, Somdyala NIM, Manraj SS, Ogunbiyi OJ,
Dzamalala CP, Finesse A, et al: Rising prostate cancer incidence in
Sub-saharan africa: A trend analysis of data from the african
cancer registry network. Cancer Epidemiol Biomarkers Prev.
30:158–165. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Culp MB, Soerjomataram I, Efstathiou JA,
Bray F and Jemal A: Recent global patterns in prostate cancer
incidence and mortality rates. Eur Urol. 77:38–52. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Schafer EJ, Jemal A, Wiese D, Sung H,
Kratzer TB, Islami F, Dahut WL and Knudsen KE: Disparities and
trends in genitourinary cancer incidence and mortality in the USA.
Eur Urol. 84:117–126. 2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rawla P: Epidemiology of prostate cancer.
World J Oncol. 10:63–89. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bagri A, Tessier-Lavigne M and Watts RJ:
Neuropilins in tumor biology. Clin Cancer Res. 15:1860–1864.
2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chaudhary B, Khaled YS, Ammori BJ and
Elkord E: Neuropilin 1: Function and therapeutic potential in
cancer. Cancer Immunol Immunother. 63:81–99. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Staton CA, Kumar I, Reed MWR and Brown NJ:
Neuropilins in physiological and pathological angiogenesis. J
Pathol. 212:237–248. 2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Guttmann-Raviv N, Kessler O, Shraga-Heled
N, Lange T, Herzog Y and Neufeld G: The neuropilins and their role
in tumorigenesis and tumor progression. Cancer Lett. 231:1–11.
2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bachelder RE, Crago A, Chung J, Wendt MA,
Shaw LM, Robinson G and Mercurio AM: Vascular endothelial growth
factor is an autocrine survival factor for Neuropilin-expressing
breast carcinoma cells. Cancer Res. 61:5736–5740. 2001.PubMed/NCBI
|
|
11
|
Parikh AA, Fan F, Liu WB, Ahmad SA,
Stoeltzing O, Reinmuth N, Bielenberg D, Bucana CD, Klagsbrun M and
Ellis LM: Neuropilin-1 in human colon cancer: Expression,
regulation, and role in induction of angiogenesis. Am J Pathol.
164:2139–2151. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hong TM, Chen YL, Wu YY, Yuan A, Chao YC,
Chung YC, Wu MH, Yang SC, Pan SH, Shih JY, et al: Targeting
neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer
Res. 13:4759–4768. 2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Dong Y, Ma WM, Shi ZD, Zhang ZG, Zhou JH,
Li Y, Zhang SQ, Pang K, Li BB, Zhang WD, et al: Role of NRP1 in
bladder cancer pathogenesis and progression. Front Oncol.
11(685980)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fakhari M, Pullirsch D, Abraham D, Paya K,
Hofbauer R, Holzfeind P, Hofmann M and Aharinejad S: Selective
upregulation of vascular endothelial growth factor receptors
neuropilin-1 and -2 in human neuroblastoma. Cancer. 94:258–263.
2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kiełb P, Kowalczyk K, Gurwin A, Nowak Ł,
Krajewski W, Sosnowski R, Szydełko T and Małkiewicz B: Novel
histopathological biomarkers in prostate cancer: Implications and
perspectives. Biomedicines. 11(1552)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fuh G, Garcia KC and de Vos AM: The
interaction of neuropilin-1 with vascular endothelial growth factor
and its receptor flt-1. J Biol Chem. 275:26690–26695.
2000.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sharma S, Ehrlich M, Zhang M, Blobe GC and
Henis YI: NRP1 interacts with endoglin and VEGFR2 to modulate VEGF
signaling and endothelial cell sprouting. Commun Biol.
7(112)2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Carmeliet P, Ferreira V, Breier G,
Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A,
Harpal K, Eberhardt C, et al: Abnormal blood vessel development and
lethality in embryos lacking a single VEGF allele. Nature.
380:435–439. 1996.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Ferrara N, Carver-Moore K, Chen H, Dowd M,
Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ and Moore MW:
Heterozygous embryonic lethality induced by targeted inactivation
of the VEGF gene. Nature. 380:439–442. 1996.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Zhang S, Zhau HE, Osunkoya AO, Iqbal S,
Yang X, Fan S, Chen Z, Wang R, Marshall FF, Chung LW and Wu D:
Vascular endothelial growth factor regulates myeloid cell
leukemia-1 expression through neuropilin-1-dependent activation of
c-MET signaling in human prostate cancer cells. Mol Cancer.
9(9)2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang P, Chen L, Zhou F, He Z, Wang G and
Luo Y: NRP1 promotes prostate cancer progression via modulating
EGFR-dependent AKT pathway activation. Cell Death Dis.
14(159)2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rizzolio S, Rabinowicz N, Rainero E,
Lanzetti L, Serini G, Norman J, Neufeld G and Tamagnone L:
Neuropilin-1-dependent regulation of EGF-receptor signaling. Cancer
Res. 72:5801–5811. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Gu C, Limberg BJ, Whitaker GB, Perman B,
Leahy DJ, Rosenbaum JS, Ginty DD and Kolodkin AL: Characterization
of neuropilin-1 structural features that confer binding to
semaphorin 3A and vascular endothelial growth factor 165. J Biol
Chem. 277:18069–18076. 2002.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Maden CH, Gomes J, Schwarz Q, Davidson K,
Tinker A and Ruhrberg C: NRP1 and NRP2 cooperate to regulate
gangliogenesis, axon guidance and target innervation in the
sympathetic nervous system. Dev Biol. 369:277–285. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Narazaki M and Tosato G: Ligand-induced
internalization selects use of common receptor neuropilin-1 by
VEGF165 and semaphorin3A. Blood. 107:3892–3901. 2006.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Miao HQ, Soker S, Feiner L, Alonso JL,
Raper JA and Klagsbrun M: Neuropilin-1 mediates
collapsin-1/semaphorin III inhibition of endothelial cell motility:
Functional competition of collapsin-1 and vascular endothelial
growth factor-165. J Cell Biol. 146:233–242. 1999.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Acevedo LM, Barillas S, Weis SM, Göthert
JR and Cheresh DA: Semaphorin 3A suppresses VEGF-mediated
angiogenesis yet acts as a vascular permeability factor. Blood.
111:2674–2680. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Goshima Y, Ito T, Sasaki Y and Nakamura F:
Semaphorins as signals for cell repulsion and invasion. J Clin
Invest. 109:993–998. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Chédotal A, Kerjan G and Moreau-Fauvarque
C: The brain within the tumor: New roles for axon guidance
molecules in cancers. Cell Death Differ. 12:1044–1056.
2005.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Bagnard D, Sainturet N, Meyronet D,
Perraut M, Miehe M, Roussel G, Aunis D, Belin MF and Thomasset N:
Differential MAP kinases activation during semaphorin3A-induced
repulsion or apoptosis of neural progenitor cells. Mol Cell
Neurosci. 25:722–731. 2004.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Bachelder RE, Lipscomb EA, Lin X, Wendt
MA, Chadborn NH, Eickholt BJ and Mercurio AM: Competing autocrine
pathways involving alternative neuropilin-1 ligands regulate
chemotaxis of carcinoma cells. Cancer Res. 63:5230–5233.
2003.PubMed/NCBI
|
|
32
|
Miao HQ, Lee P, Lin H, Soker S and
Klagsbrun M: Neuropilin-1 expression by tumor cells promotes tumor
angiogenesis and progression. FASEB J. 14:2532–2539.
2000.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tse BWC, Volpert M, Ratther E, Stylianou
N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M,
Butler MS, et al: Neuropilin-1 is upregulated in the adaptive
response of prostate tumors to androgen-targeted therapies and is
prognostic of metastatic progression and patient mortality.
Oncogene. 36:3417–3427. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Jia H, Cheng L, Tickner M, Bagherzadeh A,
Selwood D and Zachary I: Neuropilin-1 antagonism in human carcinoma
cells inhibits migration and enhances chemosensitivity. Br J
Cancer. 102:541–552. 2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Buyyounouski MK, Choyke PL, McKenney JK,
Sartor O, Sandler HM, Amin MB, Kattan MW and Lin DW: Prostate
cancer-major changes in the American Joint Committee on Cancer
eighth edition cancer staging manual. CA Cancer J Clin. 67:245–253.
2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
van Leenders GJLH, van der Kwast TH,
Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, Litjens G,
McKenney JK, Melamed J, Mottet N, et al: The 2019 international
society of urological pathology (ISUP) consensus conference on
grading of prostatic carcinoma. Am J Surg Pathol. 44:e87–e99.
2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Cornford P, van den Bergh RCN, Briers E,
Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer
G, De Santis M, Farolfi A, et al: EAU-EANM-ESTRO-ESUR-ISUP-SIOG
guidelines on prostate Cancer-2024 update. Part I: Screening,
diagnosis, and local treatment with curative intent. Eur Urol.
86:148–163. 2024.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kiełb P, Kaczorowski M, Kowalczyk K,
Piotrowska A, Nowak Ł, Krajewski W, Chorbińska J, Dudek K, Dzięgiel
P, Hałoń A, et al: Role of IL-17A and IL-17RA in prostate cancer
with lymph nodes metastasis: Expression patterns and clinical
significance. Cancers (Basel). 15(4578)2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Talagas M, Uguen A, Garlantezec R,
Fournier G, Doucet L, Gobin E, Marcorelles P, Volant A and DE
Braekeleer M: VEGFR1 and NRP1 endothelial expressions predict
distant relapse after radical prostatectomy in clinically localized
prostate cancer. Anticancer Res. 33:2065–2075. 2013.PubMed/NCBI
|
|
40
|
Vanveldhuizen PJ, Zulfiqar M, Banerjee S,
Cherian R, Saxena NK, Rabe A, Thrasher JB and Banerjee SK:
Differential expression of Neuropilin-1 in malignant and benign
prostatic stromal tissue. Oncol Rep. 10:1067–1071. 2003.PubMed/NCBI
|
|
41
|
Yacoub M, Coulon A, Celhay O, Irani J,
Cussenot O and Fromont G: Differential expression of the semaphorin
3A pathway in prostatic cancer. Histopathology. 55:392–398.
2009.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hu P, Chung LWK, Berel D, Frierson HF,
Yang H, Liu C, Wang R, Li Q, Rogatko A and Zhau HE: Convergent
RANK- and c-Met-mediated signaling components predict survival of
patients with prostate cancer: An interracial comparative study.
PLoS One. 8(e73081)2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Detre S, Saclani Jotti G and Dowsett M: A
‘quickscore’ method for immunohistochemical semiquantitation:
Validation for oestrogen receptor in breast carcinomas. J Clin
Pathol. 48:876–878. 1995.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Fedchenko N and Reifenrath J: Different
approaches for interpretation and reporting of immunohistochemistry
analysis results in the bone tissue-a review. Diagn Pathol.
9(221)2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Daneshmand S, Quek ML, Stein JP,
Lieskovsky G, Cai J, Pinski J, Skinner EC and Skinner DG: Prognosis
of patients with lymph node positive prostate cancer following
radical prostatectomy: Long-term results. J Urol. 172:2252–2255.
2004.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Schumacher MC, Burkhard FC, Thalmann GN,
Fleischmann A and Studer UE: Good outcome for patients with few
lymph node metastases after radical retropubic prostatectomy. Eur
Urol. 54:344–352. 2008.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Moreira DM, Presti JC Jr, Aronson WJ,
Terris MK, Kane CJ, Amling CL and Freedland SJ: Natural history of
persistently elevated prostate specific antigen after radical
prostatectomy: Results from the SEARCH database. J Urol.
182:2250–2255. 2009.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ploussard G, Fossati N, Wiegel T, D'Amico
A, Hofman MS, Gillessen S, Mottet N, Joniau S and Spratt DE:
Management of persistently elevated prostate-specific antigen after
radical prostatectomy: A systematic review of the literature. Eur
Urol Oncol. 4:150–169. 2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Moreira DM, Presti JC Jr, Aronson WJ,
Terris MK, Kane CJ, Amling CL and Freedland SJ: Definition and
preoperative predictors of persistently elevated prostate-specific
antigen after radical prostatectomy: Results from the Shared Equal
Access Regional Cancer Hospital (SEARCH) database. BJU Int.
105:1541–1547. 2010.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Preisser F, Chun FKH, Pompe RS, Heinze A,
Salomon G, Graefen M, Huland H and Tilki D: Persistent
Prostate-specific antigen after radical prostatectomy and its
impact on oncologic outcomes. Eur Urol. 76:106–114. 2019.PubMed/NCBI View Article : Google Scholar
|
